Bot Detector
IJPC Seal
Download FREE Sample Issue or Article
LEARN MORE
Subscribe Today
A subscription to IJPC provides on-line access to full-text, full-color, printable PDF copies of your subscribed issues, individual articles, and purchased archives.

Litigating the Legality of Compounding: The Medical Center Pharmacy Case

Author(s):  Gibbs Jeffrey N

Issue:  May/Jun 2008 - Pain Management
View All Articles in Issue

Page(s):  238-241

Litigating the Legality of Compounding: The Medical Center Pharmacy Case Page 1
Litigating the Legality of Compounding: The Medical Center Pharmacy Case Page 2
Litigating the Legality of Compounding: The Medical Center Pharmacy Case Page 3
Litigating the Legality of Compounding: The Medical Center Pharmacy Case Page 4

Download in electronic PDF format for $75

Abstract:  The question of whether all compounded drugs are “new drugs” has been disputed in the United States for over 15 years. The Federal Food, Drug, and Cosmetic Act generally requires that “new drugs” obtain U.S. Food and Drug Administration approval before being sold in the U.S. Between 1938 and the late 1980s, the U.S. Food and Drug Administration did not assert that compounded drugs are subject to the new drug provisions. Then, the U.S. Food and Drug Administration developed and advanced a new theory. As articulated in a 1989 memorandum by a U.S. Food and Drug Administration attorney, the U.S. Food and Drug Administration could take the position that compounded drugs were new drugs and therefore subject to new drug approval requirements. Although the memorandum acknowledged that this represented a significant change in policy, the U.S. Food and Drug Administration adopted this legal theory. Their position that compounded drugs are new drugs led to a clash between the agency and compounding pharmacies. Congress

Related Keywords: pharmacy regulation, pharmacy law, legal cases, U.S. Food and Drug Administration, FDA, unapproved new drugs

Related Categories: LEGAL, PROFESSIONAL ISSUES

Printer-Friendly Version



Related Articles from IJPC
Title/Author
(Click for Abstract / Details / Purchase)
Issue/​Page
View/Buy
Litigating the Legality of Compounding: The Medical Center Pharmacy Case
Gibbs Jeffrey N
May/Jun 2008
Pg. 238-241

Discrepancies in the Law and the U.S. Food and Drug Administration Pharmacy Compounding Compliance Policy Guidelines
Allen Loyd V Jr
Jul/Aug 2016
Pg. 351

View Sample
U.S. Food and Drug Administration Inspections: Guide to a Successful Outcome for 503A Sterile Compounding Pharmacies
Yoch Doug
Mar/Apr 2017
Pg. 95-102

PreScription: 2017 Pharmacy Compounding Issues: The U.S. Food and Drug Administration, Harzardous Drugs, and Wasted Drugs
Allen Loyd V Jr
Sep/Oct 2017
Pg. 356

U.S. Food and Drug Administration "Evaluation Criteria" for Difficult to Compound Drugs
Allen Loyd V Jr
Nov/Dec 2015
Pg. 487-488

PostScription: Thousands of Unapproved New Drugs are on the U.S. Market, Part 1
Allen Loyd V Jr
Jul/Aug 2007
Pg. 350-351

Nominations of Difficult to Compound Drugs to the U.S. Food and Drug Administration--Pharmacy Compounding Advisory Committee: Part 1
Allen Loyd V Jr
Sep/Oct 2015
Pg. 389-390

U.S. Food and Drug Administration Proposed Guidance Document: Compounding Animal Drugs from Bulk Substances
Miller David G
Jul/Aug 2015
Pg. 303-305

U.S. Food and Drug Administration Inspection Authority: How to Know Whether U.S. Food and Drug Administration Inspectors Are Crossing the Line
Snow Stephen T
, Stannard Robert W, Bellis Jennifer, Moss Carrie A
Jan/Feb 2019
Pg. 32-33

Finally: A Final U.S. Food and Drug Administration Memorandum of Understanding, but It's Flawed
Brunner Scott
Jul/Aug 2020
Pg. 296-297

PostScription: Thousands of Unapproved New Drugs are on the U.S. Market, Part 2
Allen Loyd V Jr
Sep/Oct 2007
Pg. 438-439

The U.S. Food and Drug Administration Responds to the International Academy of Compounding Pharmacists' Outsourcing Letter
Miller David G
May/Jun 2014
Pg. 208

PreScription: Compounding Pharmacy Issues for 2017
Allen Loyd V Jr
Jan/Feb 2017
Pg. 4

Applying Quality of Design Concepts to Pharmacy Compounding
Timko Robert J
Nov/Dec 2015
Pg. 453-463

U.S. Food and Drug Administration List of Drugs NOT to be Used in Compounded Medications for Humans (The Negative List)
Nov/Dec 2016
Pg. 457-458

Pharmacies on the Frontline: Responding to the COVID-19 Pandemic
McElhiney Linda F
Jul/Aug 2020
Pg. 287-295

The U.S. Food and Drug Administration Takes Aim at Compounded Thyroid Hormone
Brunner Scott
Jan/Feb 2023
Pg. 22-23

Allowing Compounding Pharmacies to Address Drug Shortages
Broughel James
Mar/Apr 2022
Pg. 100-109

Standing Together Fixing the Drug Quality and Security Act
Miller David G
Mar/Apr 2015
Pg. 104-106

Final Guidance for Pharmacy Compounding of Human Drug Products Under Section 503A
Blankenship Cynthia E
Sep/Oct 2014
Pg. 379-380

Return to Top